TY  - JOUR
AU  - Domínguez-Soto, Ángeles
AU  - Simón-Fuentes, Miriam
AU  - de Las Casas-Engel, Mateo
AU  - Cuevas, Víctor D
AU  - López-Bravo, María
AU  - Domínguez-Andrés, Jorge
AU  - Saz-Leal, Paula
AU  - Sancho, David
AU  - Ardavín, Carlos
AU  - Ochoa-Grullón, Juliana
AU  - Sánchez-Ramón, Silvia
AU  - Vega, Miguel A
AU  - Corbí, Angel L
PY  - 2018
DO  - 10.4049/jimmunol.1701093
UR  - http://hdl.handle.net/20.500.12105/15161
AB  - IVIg is an approved therapy for immunodeficiency and for several autoimmune and inflammatory diseases. However, the molecular basis for the IVIg anti-inflammatory activity remains to be fully explained and cannot be extrapolated from studies on animal...
LA  - eng
PB  - American Association of Immunologists (AAI)
KW  - Activins
KW  - Animals
KW  - Anti-Inflammatory Agents
KW  - Cells, Cultured
KW  - Chemokine CCL2
KW  - Enzyme Activation
KW  - Granulocyte-Macrophage Colony-Stimulating Factor
KW  - Humans
KW  - Immune Tolerance
KW  - Immunoglobulins, Intravenous
KW  - Inflammation
KW  - Interleukin-6
KW  - JNK Mitogen-Activated Protein Kinases
KW  - Lipopolysaccharides
KW  - Macrophages
KW  - Mice
KW  - Monocytes
KW  - STAT5 Transcription Factor
TI  - IVIg Promote Cross-Tolerance against Inflammatory Stimuli In Vitro and In Vivo.
TY  - journal article
ER  -